# REDucing Hot FLASHes in Women Using Endocrine Therapy.

> **NCT06106529** · PHASE3 · RECRUITING · sponsor: **Reinier de Graaf Groep** · enrollment: 260 (estimated)

## Conditions studied

- Breast Cancer
- Hot Flash Due to Medication

## Interventions

- **DRUG:** Oxybutynin
- **DRUG:** Venlafaxine

## Key facts

- **NCT ID:** NCT06106529
- **Lead sponsor:** Reinier de Graaf Groep
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-03
- **Primary completion:** 2029-01-01
- **Final completion:** 2029-01-01
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06106529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06106529, "REDucing Hot FLASHes in Women Using Endocrine Therapy.". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06106529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*